Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 11Thoracic 7CNS 6Gastrointestinal 4Genitourinary 3Gynecologic 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 184Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 94Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × enzastaurin × Breast × Clear all
NCT00451555 2019-11-01

Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer

Eli Lilly and Company

Phase 2 Completed
156 enrolled 15 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡